"William Blair argues that Cardinal Health's distribution platform creates a 'durable competitive moat' that supports 'high-growth specialty upside.' The firm cites the scale of Cardinal Health's distribution capabilities and the breadth of non-distribution services as key advantages."
"Cardinal Health stock has returned 48% over the past year and 240% over five years, reframing the 'stealth compounder' thesis in real numbers. Those returns underscore why William Blair sees durable upside ahead."
William Blair launched coverage of Cardinal Health and McKesson with Outperform ratings, emphasizing Cardinal Health's durable competitive advantages and growth potential in specialty medicines. Cardinal Health has shown significant stock returns, with a 48% increase over the past year and 240% over five years. The firm cites Cardinal Health's distribution scale and non-distribution services as key strengths. The upcoming earnings reports for both companies are anticipated, with Cardinal Health's Q3 FY2026 results due on April 30 and McKesson's on May 7.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]